Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized mRNA Vaccine in Refractory Rhabdomyosarcoma
NCT06932861Phase 1Recruiting
- Start
- Oct 2025
- Primary completion
- May 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of personalized neoantigen mRNA vaccine in rhabdomyosarcoma (RMS). Primary endpoint: Adverse Event. Started Oct 2025; status: recruiting.
02
Drugs
personalized neoantigen mRNA vaccine
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT06932861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932861.